Britain and America have finalized a key trade agreement that will preserve zero import taxes on UK drug shipments entering the US market.
Agreement Details of the Accord
As part of the deal, the UK has agreed to raise spending on medicines through the NHS. This commitment secures that duties on these crucial exports will stay at nothing for a period of 36 months.
This development is in response to recent warnings to dramatically increase import taxes on branded drug products, with increases mentioned reaching 100%.
"This arrangement with the Britain strengthens the worldwide climate for innovative medicines and establishes much-needed balance to transatlantic medicine commerce," an announcement noted.
Economic Importance
Drugs are one of the the United Kingdom's most significant goods shipped to the America, which is clearly the largest destination for major UK drugmakers.
Export figures reveal that in the one-year period to the end of September, the UK shipped pharmaceutical products totaling £11.1bn to the US. This value accounted for 17.4% of total UK exports in that timeframe.
"This deal protects jobs, boosts funding and facilitates the UK to establish itself as a global hub for medical research," the Business and Trade Secretary commented.
Specific British Pledges
The agreement includes several key changes from the UK:
- Higher Cost Ceiling: The UK will increase the affordability limit at which it judges new treatments to be too expensive by 25%.
- Boosted Medicine Funding: There is a aim to increase overall NHS spending on drugs from 0.3 percent of GDP to 0.6 percent over the next decade.
- Payback Limit: The sum manufacturers must refund to the NHS to stay within budget will be restricted at fifteen percent. In the past, refunds topped 20%.
Industry Background
This agreement comes amid a protracted tension between the pharmaceutical industry and the ministers over medicine costs and regulatory access.
This friction were heightened by claims that American consumers were paying a premium for the same drugs than consumers in the other developed nations.
Recently, several significant manufacturing plans in the UK have been halted or scrapped, while major expansions have been directed toward American operations.
The Science Minister stated that the NHS had to spend more on medicines, noting that its spending on drugs had shrunk as a share of its total funding over the past decade.
